Oral Communications

Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Factor Xa Inhibitors in Patients with Acute Major Bleeding

At Thursday’s DOACs and Beyond: Translational Aspects Oral Communications Session, Janet Leeds, Ph.D. of Portola Pharmaceuticals Inc. presented findings on her research regarding the validation of a pharmacokinetic (PK) and pharmacodynamic (PD) model of andexanet alfa, an investigational agent used for the reversal of anticoagulation with factor Xa (FXa) inhibitor therapie

Read More